METHODS: Plasma levels of HMGB1 were measured by ELISA in non-pregnant women with (n=44) and without (n=53 controls) uRPL. Their platelets and plasma-derived microvesicles (MVs) were also assayed for HMGB1. Endometrial biopsies were taken in selected uRPL (n=5) and control women (n=5) and the tissue expression of HMGB1 was determined by western blot and immunohistochemistry (IHC).
RESULTS: plasma levels of HMGB1 were significantly higher in women with uRPL than in control women. HMGB1 content in platelets and MVs obtained from women with uRPL was significantly higher than that obtained from control women. HMGB1 expression in endometrium was higher in tissues obtained from women with uRPL than in tissues obtained from control women. IHC analysis revealed that HMGB1 is expressed in endometrium with different patterns between uRPL and control women.
CONCLUSIONS: HMGB1 could be involved in uRPL.
方法:通过ELISA在有(n=44)和没有(n=53对照)uRPL的非妊娠妇女中测量HMGB1的血浆水平。还测定了它们的血小板和血浆衍生的微泡(MV)的HMGB1。在选定的uRPL(n=5)和对照妇女(n=5)中进行子宫内膜活检,并通过蛋白质印迹和免疫组织化学(IHC)确定HMGB1的组织表达。
结果:患有uRPL的女性血浆HMGB1水平明显高于对照组。从患有uRPL的女性获得的血小板和MV中的HMGB1含量显著高于从对照女性获得的。从患有uRPL的女性获得的组织中子宫内膜中的HMGB1表达高于从对照女性获得的组织。IHC分析显示,HMGB1在子宫内膜中表达,在uRPL和对照妇女之间具有不同的模式。
结论:HMGB1可能参与uRPL。